| IDP Stock | | | EUR 152.90 2.90 1.93% |
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
Biogen Inc Company Z Score Analysis
Biogen's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Biogen Z Score | | | | 3.0 |
Most of Biogen's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biogen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| First Factor | = | 1.2 * ( | Working Capital | / | Total Assets ) |
|
| Second Factor | = | 1.4 * ( | Retained Earnings | / | Total Assets ) |
|
| Thrid Factor | = | 3.3 * ( | EBITAD | / | Total Assets ) |
|
| Fouth Factor | = | 0.6 * ( | Market Value of Equity | / | Total Liabilities ) |
|
| Fifth Factor | = | 0.99 * ( | Revenue | / | Total Assets ) |
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
According to the company's disclosures, Biogen Inc has a Z Score of 3.0. This is 55.56% lower than that of the Healthcare sector and significantly higher than that of the
Drug Manufacturers—General industry. The z score for all Germany stocks is 65.6% higher than that of the company.
Biogen Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biogen's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biogen could also be used in its relative valuation, which is a method of valuing Biogen by comparing valuation metrics of similar companies.
Biogen is currently under evaluation in z score category among its peers.
Biogen Fundamentals
About Biogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biogen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Biogen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Biogen Stock
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock: Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.